• Home
  • NEW DAY MEDICINE
  • 11 (85) 2025
  • 75 -11 (85) 2025 - Mamarizaev A.A., Azimova S.B. - HOW GENETIC VARIATIONS IN ESR1 IMPACT PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

75 -11 (85) 2025 - Mamarizaev A.A., Azimova S.B. - HOW GENETIC VARIATIONS IN ESR1 IMPACT PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

HOW GENETIC VARIATIONS IN ESR1 IMPACT PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

Nurova G.U. - Andijan State Medical Institute

Azimova S.B. - Tashkent State Medical University

Rustamov U.M. - Andijan State Medical Institute

Resume

Polymorphism PvuII (rs2234693) in the ESR1 gene (estrogen receptor alpha) may play a significant role in the pathogenesis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). This single nucleotide polymorphism (T/C) can modulate ESR1 expression and receptor activity, thereby influencing tissue responses to estrogens, cell proliferation, apoptosis, and inflammation within the prostate. In this study, we evaluated the distribution of the T (major) and C (minor) alleles and corresponding genotypes (T/T, T/C, C/C) among patients with lower urinary tract symptoms (LUTS) due to BPH and PCa and compared them to healthy controls. Our findings indicate that the minor C allele is more frequent among affected patients, suggesting an association with increased susceptibility to prostate pathology. These results highlight potential value of the ESR1 PvuII polymorphism as a biomarker for risk stratification and as a candidate for personalized preventive and therapeutic strategies in prostate disorders.

Keywords: ESR1, estrogen receptor alpha, PvuII polymorphism, rs2234693, benign prostatic hyperplasia, prostate cancer, genetic susceptibility, biomarkers, LUTS, genetic variations.

First page

456

Last page

459

For citation:Mamarizaev A.A., Azimova S.B., Rustamov U.M. - HOW GENETIC VARIATIONS IN ESR1 IMPACT PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA//New Day in Medicine 11(85)2025 456-459 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

  1. Alcaraz A., Carballido-Rodrigues J. Quality of Life in patients with lower urinary tract symptoms associated with BPH: the Qualiprost study. // Int Urol Nephrol. 2016;48(5):645–656.
  2. Joniau S., Briganti A., Gontero P. et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. // Eur Urol. 2015;67(1):157–164.
  3. Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5(1):28–32.
  4. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. // Asian J Urol. 2017;4(3):148–151.
  5. Rawla P. Epidemiology of Prostate Cancer. // World J Oncol. 2019;10(2):63–89.
  6. Shih HJ, Huang CJ, Lin JA. et al. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. // Prostate. 2018;78(2):113–120.
  7. Sissung TM, Price DK, Del Re M. et al. Genetic variation: effect on prostate cancer. // Biochim Biophys Acta. 2014;1846:446–456.
  8. Sivonova MK, Jurečekova J, Tatarkova Z. et al. The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition. // Gen Physiol Biophys. 2017;36:487–499.
  9. Vuichoud C, Loughlin KR. Benign Prostatic Hyperplasia: epidemiology, economics and evaluation. // Can J Urol. 2015;22(Suppl 1):1–6.
  10. Wang G. et al. Genetics and biology of prostate cancer. // Genes Dev. 2018;32(17–18):1105–1140.

    file

    download